-
31.发明授权TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS 有权TETRA HYDRO吡嗪并[1,2-A]吲哚用于中央神经系统疾病的治疗
公开(公告)号：EP1370561B1
公开(公告)日：2009-02-11
申请号：EP02732459.9
申请日：2002-03-06
发明人： HEBEISEN, Paul , MATTEI, Patrizio , MULLER, Marc , RICHTER, Hans , ROEVER, Stephan , TAYLOR, Sven
IPC分类号： C07D487/04 , A61K31/4985 , A61P3/00
CPC分类号： C07D487/04
摘要： The present invention refers to chemical compounds of formula (I) as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R7 have the significance given in the description and the claims. The compounds can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea.
-
公开(公告)号：EP2010487A1
公开(公告)日：2009-01-07
申请号：EP07727442.1
申请日：2007-03-28
IPC分类号： C07D209/42 , C07D401/06 , A61K31/404 , A61P3/04
CPC分类号： C07D401/06 , C07D209/42 , C07D401/14 , C07D403/06 , C07D405/12 , C07D487/04 , C07D491/113
摘要： The present invention relates to compounds of formula (I) wherein G and R to R and R are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐，其中G和R 1至R 3和R 3如说明书和权利要求书中所定义。 该化合物可用于治疗和/或预防与H3受体调节有关的疾病。
-
公开(公告)号：EP1960383A1
公开(公告)日：2008-08-27
申请号：EP06819609.6
申请日：2006-11-20
IPC分类号： C07D401/12 , A61K31/404
CPC分类号： C07D401/12 , C07D451/06
摘要： The present invention relates to compounds of formula (I) wherein R1 to R4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
-
公开(公告)号：EP1325008B1
公开(公告)日：2005-10-05
申请号：EP01962869.2
申请日：2001-07-24
发明人： BENTLEY, Jonathan, Mark , HEBEISEN, Paul , MULLER, Marc , RICHTER, Hans , ROEVER, Stephan , MATTEI, Patrizio , TAYLOR, Sven
IPC分类号： C07D487/04 , A61K31/4985 , A61P3/10
CPC分类号： C07D487/04
摘要： The present invention refers to chemical compounds of formula (I) as well as pharmaceutically usable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1. They can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnoea.
-
公开(公告)号：EP4208456A1
公开(公告)日：2023-07-12
申请号：EP21772763.5
申请日：2021-09-01
发明人： BENZ, Joerg , GRETHER, Uwe , HORNSPERGER, Benoit , KROLL, Carsten , KUHN, Bernd , MARTIN, Rainer, E. , O'HARA, Fionn , PUELLMANN, Bernd , RICHTER, Hans , RITTER, Martin
IPC分类号： C07D403/06 , C07D403/14 , C07D413/04 , C07D413/14 , C07D487/04 , A61K31/4192 , A61K31/422 , A61P25/00
-
公开(公告)号：EP4204420A1
公开(公告)日：2023-07-05
申请号：EP21766615.5
申请日：2021-08-24
发明人： BENZ, Joerg , GRETHER, Uwe , HORNSPERGER, Benoit , KROLL, Carsten , KUHN, Bernd , MARTIN, Rainer E. , O'HARA, Fionn , RICHTER, Hans , RITTER, Martin , SCHMID, Philipp
IPC分类号： C07D487/04 , C07D491/147 , A61P25/28 , A61P29/00 , A61P35/00 , A61K31/416 , A61K31/4162
-
公开(公告)号：EP4034602A1
公开(公告)日：2022-08-03
申请号：EP20780979.9
申请日：2020-09-22
-
公开(公告)号：EP4034239A1
公开(公告)日：2022-08-03
申请号：EP20780603.5
申请日：2020-09-21
-
39.发明授权
公开(公告)号：EP2895481B1
公开(公告)日：2019-12-11
申请号：EP13762429.2
申请日：2013-09-09
发明人： BUETTELMANN, Bernd , CECCARELLI, Simona M. , KUEHNE, Holger , KUHN, Bernd , NEIDHART, Werner , OBST SANDER, Ulrike , RICHTER, Hans
IPC分类号： C07D413/14 , C07D333/36 , C07D413/04 , C07D417/04 , C07D417/14 , A61P3/10 , A61P9/10 , A61P35/00 , A61P13/12 , A61P1/16 , A61K31/381 , A61K31/427 , A61K31/4245 , A61K31/433
-
40.发明公开2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES 有权2,3-取代的4,5,6,7-吲唑或TETRAHYDROINDAZOLE AS调节剂的FXR AGAINST血脂异常和相关疾病
公开(公告)号：EP2344459A1
公开(公告)日：2011-07-20
申请号：EP09783005.3
申请日：2009-09-15
发明人： BENSON, Gregory Martin , BLEICHER, Konrad , GRETHER, Uwe , KUHN, Bernd , RICHTER, Hans , TAYLOR, Sven
IPC分类号： C07D231/56 , C07D401/12 , C07D403/12 , A61P3/06 , A61P3/10 , A61K31/416
CPC分类号： C07D231/56 , C07D401/12 , C07D403/12
摘要： This invention relates to novel indazole or 4,5,6,7-tetrahydro-indazole derivatives of formula (I) wherein R
1 to R
8 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments. The compounds are selective modulators of the farnesoid-X-receptor, preferably agonists. The farnesoid-X-receptor (FXR) is a member of the nuclear hormone receptor superfamily of transcription factors. Diseases which are affected by FXR modulators include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, diseases of cholesterol absorption, atherosclerotic disease, peripheral occlusive disease, ischemic stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, diabetic nephropathy, obesity, cholesterol gallstone disease, cholestasis/fibrosis of the liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), psoriasis, cancer, particularly gastrointestinal cancer, osteoporosis, Parkinson's disease and Alzheimer's disease. Preferred diseases (and conditions) which are affected by FXR modulators are prevention or treatment of high LDL cholesterol levels, high triglycerides, dyslipidemia, cholesterol gallstone disease, cancer, non-insulin dependent diabetes mellitus and metabolic syndrome. Particularly preferred diseases which arc affected by FXR modulators arc high LDL cholesterol, high triglyceride levels and dyslipidemia.
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.017 秒)
